An Interventional, Open-Label, Phase II Study to Investigate the Safety and Efficacy of Pf-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer
Categories (click each to see list of all clinical trials associated with that category): FPBCC CTO Studies, Thoracic (ONC)
Current Status: Open
Phase: II
Principal Investigator: Sharma, Bhavina
Contact Information:
Michaela Savine
misavine@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT07489066?term=NCT07489066&viewType=Card&rank=1#participation-criteria
Summary
PRIMARY OBJECTIVES
I. To evaluate safety and tolerability of PF-08634404 monotherapy as consolidation therapy
SECONDARY OBJECTIVES:
I. To evaluate efficacy of PF-08634404 monotherapy as consolidation therapy
II. To assess rate of ctDNA reduction or clearance following treatment
III. To evaluate additional measurement of safety of PF-08634404 monotherapy as consolidation therapy
IV. To evaluate the PK of PF-08634404 monotherapy as consolidation therapy
V. To evaluate the immunogenicity of PF-08634404 monotherapy as consolidation therapy
EXPLORATORY OBJECTIVES:
I. To characterize patient-reported functioning and impact of disease/treatment-related symptoms on global QOL and
tolerability of PF-08634404
II. To understand the relationship between PF-08634404 and the biology of the participant's disease.